多分子植物提取物药物（C5OSEW5050ESA）作为一种辅助疗法，用于克服胰腺癌细胞中的吉西他滨耐药性。
Polymolecular botanical drug of extract (C5OSEW5050ESA) as a complementary therapy to overcome gemcitabine resistance in pancreatic cancer cells.
作者信息
Yehya Ashwaq H S, Asif Muhammad, Abdul Majid Amin M S, Oon Chern E
机构信息
Vatche and Tamar Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, 90095, USA.
Institute for Research in Molecular Medicine (INFORMM), Unversiti Sains Malaysia, Penang, 11800, Malaysia.
出版信息
J Tradit Complement Med. 2022 Oct 14;13(1):39-50. doi: 10.1016/j.jtcme.2022.10.002. eCollection 2023 Jan.
BACKGROUND AND AIM
Gemcitabine remains the cornerstone of pancreatic cancer treatment, despite exhibiting a modest effect on patient survival due to the development of drug resistance. Nuvastatic™ polymolecular botanical drug () is a folklore Asian herbal medicine that is used for the treatment of a variety of ailments. However, little is known about the mechanism of actions of the Nuvastatic™ polymolecular botanical drug of as a complementary therapy in resistant pancreatic cancer. It is postulated that the proprietary extract formulation (ID: C5EOSEW5050ESA) in Nuvastatic™ may sensitise resistant pancreatic cancer cells to gemcitabine. This study was conducted to assess the cytotoxic activity and synergistic effects of C5EOSEW5050ESA in gemcitabine-resistant pancreatic cancer cells.
EXPERIMENTAL PROCEDURE
The effects of C5EOSEW5050ESA treatment on cell viability, multidrug-resistant genes, epithelial-mesenchymal transition, cellular senescence, cell death, and Notch signalling pathway were evaluated in gemcitabine-resistant Panc-1 cells.
RESULTS AND CONCLUSION
C5EOSEW5050ESA sensitised gemcitabine resistant cells towards C5EOSEW5050ESA-gemcitabine combination treatment by reducing the expression of multidrug-resistant genes and epithelial-mesenchymal transition markers in gemcitabine-resistant cells compared to the control group, possibly through the inhibition of Notch signalling. This study provides valuable insight into using C5EOSEW5050ESA as a potential complementary treatment for resistant pancreatic cancer.
背景与目的
尽管由于耐药性的产生，吉西他滨对患者生存的影响有限，但它仍是胰腺癌治疗的基石。Nuvastatic™多分子植物药（）是一种亚洲民间草药，用于治疗多种疾病。然而，关于Nuvastatic™多分子植物药作为耐药胰腺癌辅助治疗的作用机制知之甚少。据推测，Nuvastatic™中的专利提取物配方（ID：C5EOSEW5050ESA）可能使耐药胰腺癌细胞对吉西他滨敏感。本研究旨在评估C5EOSEW5050ESA在吉西他滨耐药胰腺癌细胞中的细胞毒活性和协同作用。
实验步骤
在吉西他滨耐药的Panc-1细胞中评估C5EOSEW5050ESA处理对细胞活力、多药耐药基因、上皮-间质转化、细胞衰老、细胞死亡和Notch信号通路的影响。
结果与结论
与对照组相比，C5EOSEW5050ESA通过降低吉西他滨耐药细胞中多药耐药基因和上皮-间质转化标志物的表达，使吉西他滨耐药细胞对C5EOSEW5050ESA-吉西他滨联合治疗敏感，这可能是通过抑制Notch信号实现的。本研究为将C5EOSEW5050ESA用作耐药胰腺癌的潜在辅助治疗提供了有价值的见解。
Zotero 插件